Urology

Edited by: Steve Bunk W.J. Catalona, D.S. Smith, R.L. Wolfert, T.J. Wang, H.G. Rittenhouse, T.L. Ratliff, R.B. Nadler, "Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening," JAMA-Journal of the American Medical Association, 274:1214-20, 1995. (Cited in 89 papers through August 1997) LESS WORK: Measuring free PSA in serum in screening for prostate cancer will necessitate fewer biopsies than will measuring total PSA, says urologis

Written bySteve Bunk
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Edited by: Steve Bunk
W.J. Catalona, D.S. Smith, R.L. Wolfert, T.J. Wang, H.G. Rittenhouse, T.L. Ratliff, R.B. Nadler, "Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening," JAMA-Journal of the American Medical Association, 274:1214-20, 1995. (Cited in 89 papers through August 1997)


LESS WORK: Measuring free PSA in serum in screening for prostate cancer will necessitate fewer biopsies than will measuring total PSA, says urologist William Catalona.
Comments by William J. Catalona, Department of Surgery, Washington University School of Medicine, St. Louis

The main problem with the current method of broad-based prostate cancer screenings for older men, say critics in the medical community, is that too many false-positive readings result. This high rate prompts doctors to routinely order biopsies, which often come up negative. Biopsies are costly and uncomfortable, and carry the potential for infection, notes William J. Catalona, a urologist in the department ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies